Even Slight Delays in CAR-T Therapy Administration May Increase Overall Mortality Rates
Researchers created a discrete event simulation model to assess the potential influence of wait time ranging from 1 to 9 months on CAR-T therapy efficacy.
Non-Hodgkin Lymphoma
Biosimilar Truxima Now Available for Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
Truxima (rituximab-abbs; Teva and Celltrion), a biosimilar to Rituxan (rituximab; Genentech) will be available in the US the week of November 11, 2019 for the treatment of adults with non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL).
Inferior Response Following Early Relapse in Frontline Treatment for Aggressive B-Cell Lymphomas
Of patients who experienced relapse within 6 months of frontline treatment, 17% achieved a complete response.
Determining Prognosis for Patients With Diffuse Large B-Cell Lymphoma
Researchers summarized the novel techniques and models currently being developed to improve prognostication in diffuse large B-cell lymphoma.
Long-Term Health Following the Lymphome Malin de Burkitt Chemotherapy Regimen
Survivors treated with 2 different kinds of chemotherapy experienced similar general and mental health, activity limitations, and increase in risk for mortality,
Cutaneous T-Cell Lymphoma: Do Antibiotics Make a Difference?
Cutaneous T-cell lymphomas (CTCLs) are a subgroup of non-Hodgkin lymphomas (NHLs) that include Sézary syndrome (SS) and mycosis fungoides (MF).
Physician Experience With Rituximab Affected Rate of Early Discontinuation in NHL
Early discontinuation of rituximab in patients with B-cell non-Hodgkin lymphoma was linked with worse survival.
Switching to Subcutaneous Rituximab Deemed Safe for Non-Hodgkin Lymphoma
For patients with non-Hodgkin lymphoma, switching from intravenous to subcutaneous rituximab appeared to be effective and presented no new safety issues.
Incidence of Late Events After CAR-T Therapy for Relapsed/Refractory B-Cell Malignancies
Infections occurred in 33 of 54 patients for whom data were available, and 80% of infections were treated in an outpatient setting.
Tailored Monitoring May Be Warranted in Patients With Diffuse Large B-Cell Lymphoma
The development of secondary primary malignancies in patients with diffuse large B-cell lymphoma varies in accordance with several risk factors.
